ABSTRACT
INTRODUCTION AND AIM: 1. Study of liver explants - Etiologic types of end-stage chronic liver disease (ESCLD) and acute liver failure (ALF) in adults and children. 2. Assessment of donor steatosis and incidental granulomas. 3. Post-transplant liver biopsies. MATERIAL AND METHODS: Specimens of 180 explant hepatectomies, 173 donor wedge and 30 core liver biopsies, and 58 post transplant liver biopsies received in our department from April 2013 to March 2017. RESULTS: 1. Most common causes of ESCLD in adults were: alcohol related (30.32%), hepatitis virus related (18.71%) and non-alcoholic steatohepatitis related (18.06%); and in children ≤ 12 years were: biliary atresia (27.27%), autoimmune disease (18.18%) and Wilson's disease (18.18%). Most common causes of ALF in adults and children were anti-tubercular therapy induced and idiopathic respectively. 2. Prevalence rate of moderate steatosis (between 30-60%) was 4.28%. Incidental granulomas were seen in 5 cases. 3. Most common diagnoses of post-transplant biopsies in adults included acute cellular rejection (ACR) (36.17%), recurrence of viral disease (8.51%) and moderate non-specific portal triaditis (8.51%). Among children ≤ 12 years, most common diagnoses included unremarkable liver parenchyma, ACR and ischemia/reperfusion injury. CONCLUSION: 1. Alcohol- and hepatitis- virus related ESCLD, and biliary atresia are leading indications for liver transplantation in adults and children respectively. 2. Prevalence of 4.28% of moderate steatosis, is much lower than that documented in western literature. Only 5 cases of incidental granulomas is unexpectedly low in a country endemic for tuberculosis. 3. Most common diagnoses of post-transplant liver biopsies in adults has been acute rejection, which is similar to the findings from much larger published series.
Subject(s)
End Stage Liver Disease/surgery , Liver Failure, Acute/surgery , Liver Transplantation , Tertiary Care Centers , Adolescent , Adult , Age Factors , Aged , Biliary Atresia/epidemiology , Biliary Atresia/surgery , Biopsy , Child , Child, Preschool , Donor Selection , End Stage Liver Disease/diagnosis , End Stage Liver Disease/epidemiology , Female , Graft Rejection/diagnosis , Graft Rejection/epidemiology , Hepatitis, Viral, Human/epidemiology , Hepatitis, Viral, Human/surgery , Humans , India/epidemiology , Infant , Liver Diseases, Alcoholic/epidemiology , Liver Diseases, Alcoholic/surgery , Liver Failure, Acute/diagnosis , Liver Failure, Acute/epidemiology , Liver Transplantation/adverse effects , Living Donors , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/epidemiology , Non-alcoholic Fatty Liver Disease/surgery , Prevalence , Recurrence , Risk Factors , Time Factors , Treatment Outcome , Young AdultABSTRACT
Although rare, ALF caused by disseminated HSV infection is associated with high mortality in the neonatal population. This condition is often diagnosed relatively late due to the absence of specific signs. We present a case involving a neonate with ALF submitted to living donor liver transplantation without a prior diagnosis. The patient had no skin or mucosal lesions, and IgM serology was negative for HSV-1 and HSV-2. Immunohistochemical staining of the liver explant was positive for herpes virus infection, and the patient subsequently received antiviral drug treatment, with a good outcome. Due to organ shortages and the rarity of the aforementioned condition, LT has seldom been reported for the treatment of ALF caused by herpes virus infection; however, LT may be the only option for neonates with fulminant hepatitis. The use of living donors in an urgent scenario is well established in Eastern countries and safely applicable for pediatric patients with ALF.
Subject(s)
Hepatitis, Viral, Human/surgery , Herpes Simplex/surgery , Liver Failure, Acute/surgery , Liver Transplantation/methods , Living Donors , Female , Hepatitis, Viral, Human/complications , Herpes Simplex/complications , Humans , Infant, Newborn , Liver Failure, Acute/virologyABSTRACT
CONTEXT: Orthotopic liver transplantation (OLT) is the treatment of choice for end-stage liver disease. Cirrhosis due to hepatitis C infection is the leading indication for liver transplantation worldwide. However, patients who are given transplants because of viral liver diseases often present clinical coinfections, including hepatitis B together with hepatitis D. Currently, different strategies exist for patient management before and after liver transplantation, and these are based on different protocols developed by the specialized transplantation centers. CASE REPORT: We present a rare case of a 58-year-old man with chronic hepatitis B, C and D coinfection. The patient developed cirrhosis and hepatocellular carcinoma. His treatment comprised antiviral therapy for the three viruses and OLT. The patient's outcome was satisfactory. CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recurrence of hepatitis C infection after transplantation responded successfully to standard treatment comprising peginterferon alfa-2A and ribavirin.
CONTEXTO: O transplante ortotópico de fígado (TOF) é o tratamento de escolha em pacientes com doença hepática terminal. A cirrose por hepatite C é a principal indicação de transplante hepático no mundo. No entanto, pacientes transplantados por hepatopatias virais frequentemente apresentam coinfecções, como hepatite B associada a hepatite D. Atualmente, existem diferentes estratégias de manejo em pacientes pré e pós-transplantados conforme diferentes protocolos de conduta de serviços especializados em transplante. RELATO DE CASO: Apresentamos o raro caso de um homem de 58 anos diagnosticado com as hepatites crônicas B, C e D. O paciente evoluiu com cirrose e carcinoma hepatocelular. O tratamento consistiu de terapia antiviral para os três vírus e de transplante ortotópico de fígado. O desfecho do paciente foi satisfatório. CONCLUSÃO: O transplante ortotópico de fígado, associado à terapia antiviral com entecavir antes e após o procedimento, foi eficaz na depuração sustentada dos vírus B e D. A recidiva do vírus C após o transplante respondeu com sucesso ao tratamento padrão com alfapeginterferon 2A e ribavirina.
Subject(s)
Humans , Male , Middle Aged , Carcinoma, Hepatocellular/surgery , Hepatitis, Viral, Human/drug therapy , Hepatitis, Viral, Human/surgery , Liver Cirrhosis/surgery , Liver Neoplasms/surgery , Liver Transplantation/methods , Antiviral Agents/therapeutic use , Coinfection/drug therapy , Coinfection/surgery , Hepatitis B/drug therapy , Hepatitis B/surgery , Hepatitis C/drug therapy , Hepatitis C/surgery , Hepatitis D/drug therapy , Hepatitis D/surgery , Interferon-alpha/therapeutic use , Liver Cirrhosis/virology , Polyethylene Glycols/therapeutic use , Recombinant Proteins/therapeutic use , Recurrence , Ribavirin/therapeutic use , Treatment OutcomeABSTRACT
CONTEXT: Orthotopic liver transplantation (OLT) is the treatment of choice for end-stage liver disease. Cirrhosis due to hepatitis C infection is the leading indication for liver transplantation worldwide. However, patients who are given transplants because of viral liver diseases often present clinical coinfections, including hepatitis B together with hepatitis D. Currently, different strategies exist for patient management before and after liver transplantation, and these are based on different protocols developed by the specialized transplantation centers. CASE REPORT: We present a rare case of a 58-year-old man with chronic hepatitis B, C and D coinfection. The patient developed cirrhosis and hepatocellular carcinoma. His treatment comprised antiviral therapy for the three viruses and OLT. The patient's outcome was satisfactory. CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recurrence of hepatitis C infection after transplantation responded successfully to standard treatment comprising peginterferon alfa-2A and ribavirin.
Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatitis, Viral, Human/drug therapy , Hepatitis, Viral, Human/surgery , Liver Cirrhosis/surgery , Liver Neoplasms/surgery , Liver Transplantation/methods , Antiviral Agents/therapeutic use , Coinfection/drug therapy , Coinfection/surgery , Hepatitis B/drug therapy , Hepatitis B/surgery , Hepatitis C/drug therapy , Hepatitis C/surgery , Hepatitis D/drug therapy , Hepatitis D/surgery , Humans , Interferon-alpha/therapeutic use , Liver Cirrhosis/virology , Male , Middle Aged , Polyethylene Glycols/therapeutic use , Recombinant Proteins/therapeutic use , Recurrence , Ribavirin/therapeutic use , Treatment OutcomeABSTRACT
OBJECTIVE: To better characterize the clinical outcomes of infants with herpes simplex virus (HSV) infection and identify useful correlates of disease severity. STUDY DESIGN: Infants aged ≤6 months with HSV infection treated between 1999 and 2009 were identified. In patients with concurrent hepatitis, laboratory and clinical variables were examined to identify predictors of specific outcomes, including death or the need for liver transplantation and the need for intensive care. RESULTS: Of the 15 patients enrolled, 4 (27%) had fatal disease and 2 (13%) required liver transplantation. Infants who lacked skin lesions (P = .04), had a positive HSV polymerase chain reaction result (P = .01), had more severe thrombocytopenia (P = .001), or had other organ system dysfunction (P = .002) were more likely to require intensive care. A higher International Normalized Ratio value (P = .001) and peak total bilirubin level (P = .0002) were predictive of death or the need for liver transplantation. Peak direct bilirubin level was predictive of the need for intensive care and of death or the need for liver transplantation (P = .04 and .009, respectively). CONCLUSIONS: HSV hepatitis represents a broad spectrum of disease from mild aminotransferase elevation to fulminant liver failure and death. HSV DNA detected by polymerase chain reaction, a lack of skin lesions, and the degree of coagulopathy, thrombocytopenia, and cholestasis portend unfavorable outcomes.
Subject(s)
Hepatitis, Viral, Human/mortality , Herpes Simplex/mortality , Severity of Illness Index , Bilirubin/blood , DNA, Viral/analysis , Female , Hepatitis, Viral, Human/surgery , Hepatitis, Viral, Human/virology , Humans , Infant , Infant, Newborn , Intensive Care Units, Neonatal/statistics & numerical data , Intensive Care Units, Pediatric/statistics & numerical data , International Normalized Ratio , Liver Transplantation/statistics & numerical data , Male , Polymerase Chain Reaction , Simplexvirus/genetics , Skin Diseases, Viral/epidemiology , Skin Diseases, Viral/pathology , Thrombocytopenia/epidemiologySubject(s)
Giant Cells/virology , Hepatitis, Viral, Human/surgery , Liver Transplantation , Adolescent , Antiviral Agents/therapeutic use , Biopsy , Giant Cells/pathology , Hepatitis, Viral, Human/drug therapy , Hepatitis, Viral, Human/pathology , Humans , Male , Recurrence , Ribavirin/therapeutic useABSTRACT
The purpose of the present article was to present the series operated by a Liver Transplant Group of the interior of the State of Sao Paulo, Brazil. Sixty patients were transplanted from May 2001 to May 2007. Thirty percent of the patients had alcoholic cirrhosis. 18.3% had C virus-induced cirrhosis, 10% had C virus- and alcohol-induced cirrhosis, 6% had B virus-induced cirrhosis, 13.3% had cryptogenic cirrhosis, 8.3% autoimmune cirrhosis, 13.3% had familial amyloidotic polyneuropathy (FAP), and 13.3% had hepatocellular carcinomas. The series was divided by a chronological criterion into two periods: A (n = 42) and B (n = 18) with the latter group operated based upon the Model for End-stage Liver Disease (MELD) criterion. Sixty-nine percent were men. Age ranged from 14 to 66 years. Period A included 12% Child A: 59.2%, Child B; 24%, Child C; and 4.8%, FAP. Period B comprises 22.2% Child A: 11.1%, Child B: 33.3%, Child C: and 33.3%, FAP. MELD scores ranged from 8 to 35 for period A and from 14 to 31 for period B. Intraoperative mortality was 2/42 patients for period A and 0/18 for period B, overall postoperative mortality was 40% including for period A, 35% among Child B and C patients, and 5% among FAP and Child A patients (P < .05) and 16.6% for period B among 11.1% Child B patients and 5.5% FAP patients; 3.3% of patients required retransplantation due to hepatic artery thrombosis. Real postoperative survival was 60% during period A and 83.3% during period B, with an overall survival rate of 67% for the two periods. The present results show levels of postoperative mortality, (especially during period B), and survival rates similar to those reported by several other centers in Brazil.
Subject(s)
Liver Transplantation/physiology , Adolescent , Adult , Aged , Brazil , Hepatitis, Viral, Human/surgery , Hospitals, University , Humans , Liver Cirrhosis/surgery , Liver Diseases/classification , Liver Diseases/surgery , Middle Aged , Retrospective StudiesSubject(s)
Liver Transplantation , Nervous System Diseases/epidemiology , Postoperative Complications , Adult , Central Nervous System Infections/epidemiology , Cerebrovascular Disorders/epidemiology , Consciousness Disorders/epidemiology , Female , Follow-Up Studies , Headache/epidemiology , Hepatitis, Viral, Human/surgery , Humans , Liver Cirrhosis/surgery , Male , Middle Aged , Seizures/epidemiology , Time FactorsSubject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Hepatitis, Viral, Human/mortality , Hepatitis, Viral, Human/surgery , Incidence , Liver Transplantation , PrognosisABSTRACT
O transplante de fígado alterou o prognóstico dos portadores de hepatopatias em fase terminal inclusive aquelas produzidas por vírus. Cirrose devida a hepatite crônica de etiologia nao-A, nao B é a indicaçao mais comum para o transplante. Tais doenças, contudo, sao passíveis de recidiva. As taxas de reinfecçao e recidiva da doença sao às vezes tao elevadas que tornam a indicaçao motivo de sérias controvérsias. O objetivo deste artigo é rever os dados mais atuais no que diz respeito à indicaçao do transplante de fígado para doenças hepáticas de etiologia viral. Tem sido observado que o tratamento de fígado portadores do vírus B, apesar da alta incidência de recidiva da infecçao e da doença, vem sendo realizado em diversos centros. Em relaçao à infecçao pelo vírus Delta, o transplante vem demonstrando resultados surpreendentes melhores, uma vez que a recidiva da doença somente se desenvolve na dependência da expressao dos marcadores do vírus B. Quanto ao vírus C, transplante hepático é realizado rotineiramente com bons resultados. Embora haja incidência de recidiva, a intensidade da doença hepática é, na maioria dos casos bastante discreta. É importante enfatizar que nao há métodos profiláticos ou terapêuticos eficazes para estas infecçoes no que diz respeito ao pós-transplante.